Skip to main content
RIGL logo

RIGL · Rigel Pharmaceuticals Inc · Holdings

Track RIGL — free
$42.53 -0.39 (-0.91%) At close · Nov 18 Play latest call Q3 2026 earnings call transcript
Market Cap
$800.84M
Shares
18.83M
Volume · Nov 18 304.84K Avg daily vol (3M) 252.93K

Institutional ownership from SEC Form 13F filings. Investment managers with more than $100 million in U.S. equities must disclose their positions every quarter, within 45 days of quarter-end, so the holdings shown can lag the market by up to a quarter.

Holders: 170
Total Value: $851,539,857
Total Shares: 17,685,150
Showing 1–100 of 174 holdings by value · page 1 of 2

Institutional Ownership Trend

27 quarters

Holder Concentration

Share of 13F common-share value, across 170 filers with any position, options included · Δ vs Jun 30, 2026
Top Holder
11.7%
Dec 2023 → Sep 2026 · range 10.3% – 16.0%
−0.2 pts
Top 5
43.8%
Dec 2023 → Sep 2026 · range 32.7% – 63.2%
−0.6 pts
Top 10
63.4%
Dec 2023 → Sep 2026 · range 49.1% – 81.0%
+0.2 pts
HHI
525
Dec 2023 → Sep 2026 · range 352 – 914
Broadly held−13

Who Holds RIGL

Last 8 quarters through Sep 30, 2026

Each kind of 13F filer's share of the common shares 13F filers report. Holder type comes from regulatory records, never the filer's name; style, turnover and horizon are measured from each filer's own 13F book. The quarter selector does not change this card.

Sep 30, 2026: 170 filers, like-for-like change +9.1%; actively managed books +1.6%; index-like books +24.4%.

Holder type Share Filers Change
Registered adviser 32.9% 88 -8.4%
Exempt adviser 2.3% 1 +8.1%
Adviser 2.6% 6 +4.6%
Bank 8.5% 14 -11.0%
Insurer 0.5% 2 +10.8%
Broker-dealer 0.0% 1 new
Benefit plan 0.7% 6 +24.8%
Non-US 0.8% 8 +78.3%
Holding company 21.2% 9 +45.8%
Unknown 30.5% 35 +19.4%
How the mix is measured

Shares are 13F common shares restated to today's split basis; options and principal amounts are left out. The change compares only filers with a 13F in both quarters and keeps each filer in its bucket of the later quarter on both sides; a filer that continues under a new CIK is compared through its successor. Holder type comes from each filer's current regulatory profile; client base and private funds come from the Form ADV roster current at each quarter end (rosters from December 2019, so an earlier quarter reads Unknown). Style, turnover, horizon and book size are measured from each filer's 13F book in the newest measured quarter, and Not measured means none was. Actively managed books are those measured systematic-like, concentrated or diversified active.

Excluded 1 holder with no observed 2026-06-30 13F and 3 holders with no observed 2026-09-30 13F.

Conviction and Crowding

170 13F filers, quarter ended Sep 30, 2026

Measured across every 13F filer's common-share book once the quarter's filing window closed. Crowding counts filers with high turnover or that advise private funds on Form ADV.

Conviction holders
3
1.76% of filers hold it in their top 10
Jun 30, 2026: 2
Holders above 5%
1
median weight 0.001%
Jun 30, 2026: 1
Crowding
34.1%
of shares outstanding, 86th percentile
Jun 30, 2026: 37.8%
Private-fund advisers
21.4%
of shares outstanding
Institutional ownership
94.7%
97.9% of the estimated free float
Top 10 holders
63.4%
of 13F shares, Herfindahl 0.052
Active holders
+1.6%
like-for-like share change of active filers
5% stakes on record
6
0 13D, 6 13G (5 institutional, 1 passive, 0 exempt)
How long holders have held it value-weighted 12.5 quarters
Under 1 year 15.0% 1 to 3 years 41.8% 3 years or more 43.2% Since coverage start 0.000%

Managers in the top fifth by current three-year FundScore alpha were net buyers of $17,004,660 (7 buying, 5 selling).

Estimated Holder Cost Basis

Quarter ended Sep 30, 2026, on that quarter's share basis

Estimated, never filed: each 13F buy is costed at its quarter's average traded price and each sale keeps the average cost, so this is what holders paid on average if they traded evenly through each quarter.

Estimated avg cost
$33.46
estimated per share
Jun 30, 2026: $30.22
Quarter-end price
$48.15
implied by 13F values
Estimated gain or loss
+43.9%
price against the estimated cost
Estimated at a loss
0.000%
of costed 13F value

Estimated cost covers 38.3% of the 13F shares; positions already held when a filer's 13F history starts, or bought in a quarter without a trusted average price, have no estimate.

Shared Holders

Companies RIGL's active holders also own, quarter ended Sep 30, 2026
# Company Shared holders
1 IRWD Ironwood Pharmaceuticals Inc 3
2 EOLS Evolus, Inc. 3
3 KURA Kura Oncology, Inc. 3
4 AXGN Axogen, Inc. 3
5 KNSA Kiniksa Pharmaceuticals International, plc 3
6 IOVA Iovance Biotherapeutics, Inc. 3
7 BNTX BioNTech SE 3
8 SNY Sanofi 3
9 TOST Toast, Inc. 3
10 EW Edwards Lifesciences Corp 3

Shareholder Targets

13F filers that own its peers but not RIGL, quarter ended Sep 30, 2026

Found through its holder-overlap peers: IRWD, EOLS, KURA, AXGN, KNSA, IOVA, BNTX, SNY, TOST, EW, MDT, AMZN, GOOGL. 6,641 filers in all.

# Filer In peers
1 Capital Research Global Investors Adviser, Diversified active $66,622,867,298 3 held
2 Capital World Investors Adviser, Diversified active $63,164,266,855 3 held
3 Amundi Holding company, Index-like $37,698,188,801 10 held
4 Berkshire Hathaway Inc Insurer, Concentrated $36,374,651,401 1 held
5 Capital International Investors Adviser, Diversified active $35,179,023,691 3 held
6 Fisher Asset Management, LLC Adviser, Diversified active $23,878,350,991 7 held
7 ARROWSTREET CAPITAL, LIMITED PARTNERSHIP Registered adviser, Diversified active $20,858,284,321 13 held
8 Mitsubishi UFJ Asset Management Co., Ltd. Unknown, Index-like $18,607,235,910 7 held
9 JENNISON ASSOCIATES LLC Registered adviser, Diversified active $18,601,996,987 4 held
10 BANK OF MONTREAL /CAN/ Bank, Diversified active $17,576,514,719 8 held

Fund Ownership of RIGL by Fund Type

Registered funds' Form N-PORT reports for the quarter ended Jun 30, 2026

Index funds and index ETFs hold 19.29% of shares outstanding.

Fund type Of shares outstanding Shares
Index funds 3.52% 662,933
Index ETFs 15.77% 2,968,940
Active ETFs 3.07% 578,169
Active funds 7.07% 1,330,545
Unclassified 4.06% 764,030
All registered funds 33.48% 6,304,617
How fund types are measured

Each fund series counts once, with its latest Form N-PORT report dated inside the quarter; only long share positions count, restated to today's split basis. The fund type is the series' latest Form N-CEN answer on or before the quarter end (the index-fund box and the exchange-traded flag), never its name. Unclassified funds have no usable N-CEN; unit investment trusts are among them, so index ownership is a floor. Funds sit inside their advisers' 13F reports, so these shares overlap the 13F figures and are never added to them.

Quarterly Activity

vs Jun 30, 2026
New
32
Increased
63
Decreased
50
Sold Out
19
Unchanged
24

New and Sold Out count only filers that reported a 13F for both quarters: a first-time filer's book is not a buy, and a fund that has not filed, or withheld its positions under confidential treatment, has not sold.

Holder count: +11
Institutional value: +32.9%
Shares held: +7.9%

Top Buyers

vs Jun 30, 2026
Institution Added Now Holds Open

Top Sellers

vs Jun 30, 2026
Institution Sold Now Holds Open

Top New Positions

vs Jun 30, 2026
Institution Acquired Value (USD) Open

Top Sold-Out Positions

vs Jun 30, 2026
Institution Previously Held Last Value (USD) Open
Showing 100 of 174
Export CSV
Holder Value (USD) % of 13F Shares Own % Change Type Filed Open

Showing the top 100 of 174 holders. Create a free account to see every holder, past quarters, search, filters and CSV export.

Key facts CIK 1034842 CUSIP 766559702 13F (30d) 182 filings 156 filers Visit website Investor relations